Safety Profile From the RUBY Trial

Established safety profile for JEMPERLI + CP with over 2 years of efficacy follow-up1,2

Adverse reactions (≥10%) in patients with dMMR/MSI-H endometrial cancer who received JEMPERLI with carboplatin and paclitaxel in RUBY

RUBY adverse reactions table
RUBY adverse reactions table

Graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.

CP=carboplatin-paclitaxel; dMMR=mismatch repair deficient, MSI-H=microsatellite instability-high.

*Includes rash, rash maculo-papular, palmar-plantar erythrodysesthesia syndrome, rash pustular, skin exfoliation, vulvovaginal rash, and dermatitis bullous.

Includes hypothyroidism and immune-mediated hypothyroidism.

In patients receiving JEMPERLI + CP, 15% of patients (n=8) discontinued JEMPERLI due to adverse reactions1

  • Adverse reactions leading to discontinuation of JEMPERLI included rash maculo-papular, fatigue, general physical health deterioration, acute kidney injury, infusion-related reaction, keratitis, muscular weakness, and myelosuppression (8 patients total)1
  • The most common adverse reactions, including laboratory abnormalities (≥20%), were decreased hemoglobin, decreased white blood cell count, decreased platelets, decreased lymphocytes, increased glucose, increased alkaline phosphatase, decreased neutrophils, rash, diarrhea, increased aspartate aminotransferase, increased alanine aminotransferase, decreased sodium, hypothyroidism and hypertension1
  • Serious adverse reactions occurred in 13% of patients receiving JEMPERLI + CP; the most common serious adverse reaction was sepsis, including urosepsis (6%)1
  • Fatal adverse reactions occurred in 6% of patients receiving JEMPERLI including septic shock (3.8%) and myelosuppression (1.9%)1

Laboratory abnormalities from the RUBY trial1

Laboratory abnormalities that worsened from baseline to Grade 3 or 4 occurring in ≥10% of patients with dMMR/MSI-H endometrial cancer receiving JEMPERLI with carboplatin and paclitaxel in RUBY


RUBY laboratory abnormalities table
RUBY laboratory abnormalities table

Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.

§Increased alkaline phosphatase, increased aspartate aminotransferase and increased alanine aminotransferase worsened from baseline to Grade 3 or 4 in <10% of patients.

Line graph icon

See the RUBY trial results

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Learn about

Icon: JEMPERLI (dostarlimab-gxly) Support

Learn about support for
JEMPERLI at every step